Treatment of patients with systemic‑onset juvenile idiopathic arthritis with tacrolimus

Wang,Dongdong; Chen,Xiao; Li,Zhiping

doi:10.3892/etm.2019.7174

Treatment of patients with systemic‑onset juvenile idiopathic arthritis with tacrolimus

Authors:
- Dongdong Wang
- Xiao Chen
- Zhiping Li
View Affiliations

Affiliations: Department of Pharmacy, Children's Hospital of Fudan University, Shanghai 201102, P.R. China, Department of Pharmacy, The People's Hospital of Jiangyin, Jiangyin, Jiangsu 214400, P.R. China
Published online on: January 15, 2019 https://doi.org/10.3892/etm.2019.7174
Pages: 2305-2309
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previously, few studies have reported treatment with tacrolimus (TAC) for patients with systemic‑onset juvenile idiopathic arthritis (SOJIA). The aim of the current study was to investigate the effect of TAC on patients with SOJIA. Data were collected from the beginning of treatment with TAC to the 12‑month endpoint, which was defined as the last follow‑up. Clinical characteristics included sex, age, duration of the disease, TAC dose, erythrocyte sedimentation rate (ESR), C reactive protein (CRP), hemoglobin (Hb), platelet (PLT) and white blood cell (WB) levels, prednisolone (PDN) dose and interleukin‑6 (IL‑6) expression. The baseline characteristics of the patients were: ESR, 67.8±18.7 mm/h; CRP, 128.0±38.9 mg/l; Hb, 108.7±13.7 g/l; PLT, 416.8±90.1x109/l; WB, 26.0±10.2x109/l; PDN dose, 49.0±17.1 mg/day. Following 12 months of treatment with TAC, ESR, CRP, PLT and WB levels, and the dose of PDN required for the treatment of patients with SOIJA were all decreased compared with the baseline values. No serious adverse reactions were reported. Therefore, TAC could be an effective treatment for SOJIA.

View Figures

View References

1	Schulert GS, Minoia F, Bohnsack J, Cron RQ, Hashad S, Kon EPI, Kostik M, Lovell D, Maritsi D, Nigrovic PA, et al: Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 70:409–419. 2018. View Article : Google Scholar : PubMed/NCBI
2	Cimaz R: Systemic-onset juvenile idiopathic arthritis. Autoimmun Rev. 15:931–934. 2016. View Article : Google Scholar : PubMed/NCBI
3	Allantaz F, Chaussabel D, Stichweh D, Bennett L, Allman W, Mejias A, Ardura M, Chung W, Smith E, Wise C, et al: Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med. 204:2131–2144. 2007. View Article : Google Scholar : PubMed/NCBI
4	Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, Bossuyt X, Boutten A, Bienvenu J, Duquesne A, et al: A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 70:747–754. 2011. View Article : Google Scholar : PubMed/NCBI
5	de Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR and Martini A: Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 34:1158–1163. 1991. View Article : Google Scholar : PubMed/NCBI
6	DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, Schneider R, Stoll ML, Angeles-Han S, Milojevic D, et al: Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 64:1001–1010. 2012.PubMed/NCBI
7	Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ and Wulffraat NM: Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: Results of a prospective cohort study. Arthritis Rheumatol. 66:1034–1043. 2014. View Article : Google Scholar : PubMed/NCBI
8	Kawai S and Yamamoto K: Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patients. Rheumatology (Oxford). 45:441–444. 2006. View Article : Google Scholar : PubMed/NCBI
9	Kondo H, Abe T, Hashimoto H, Uchida S, Irimajiri S, Hara M and Sugawara S: Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: A randomized, double blind, placebo controlled dose-finding study. J Rheumatol. 31:243–251. 2004.PubMed/NCBI
10	Segarra A, Vila J, Pou L, Majo J, Arbos A, Quiles T and Piera LL: Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: A preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant. 17:655–662. 2002. View Article : Google Scholar : PubMed/NCBI
11	Suzuki K, Tsugawa K and Tanaka H: Tacrolimus for the treatment of focal segmental glomerulosclerosis resistant to cyclosporine A. Pediatr Nephrol. 21:1913–1914. 2006. View Article : Google Scholar : PubMed/NCBI
12	Mok CC, Tong KH, To CH, Siu YP and Au TC: Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: An open-labeled pilot study. Kidney Int. 68:813–817. 2005. View Article : Google Scholar : PubMed/NCBI
13	Hahn D, Hodson EM, Willis NS and Craig JC: Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. Cd001533. 2015. View Article : Google Scholar
14	Tanaka H, Tsugawa K, Nakahata T, Suzuki K and Ito E: Leukocytapheresis for the treatment of refractory systemic-onset juvenile idiopathic arthritis. Clin Rheumatol. 26:1014–1016. 2007. View Article : Google Scholar : PubMed/NCBI
15	Kimura Y, Pinho P, Walco G, Higgins G, Hummell D, Szer I, Henrickson M, Watcher S and Reiff A: Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol. 32:935–942. 2005.PubMed/NCBI
16	Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Kone-Paut I, Gandon-Laloum S, LeBideau M, et al: Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 48:1093–1101. 2003. View Article : Google Scholar : PubMed/NCBI
17	Yokota S: Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis. Curr Opin Rheumatol. 15:581–586. 2003. View Article : Google Scholar : PubMed/NCBI
18	Shimizu M, Ueno K, Ishikawa S, Tokuhisa Y, Inoue N and Yachie A: Treatment of refractory polyarticular juvenile idiopathic arthritis with tacrolimus. Rheumatology (Oxford). 53:2120–2122. 2014. View Article : Google Scholar : PubMed/NCBI
19	Tanaka H, Tsugawa K, Suzuki K, Oki ES, Nonaka K, Kimura S and Ito E: Treatment of difficult cases of systemic-onset juvenile idiopathic arthritis with tacrolimus. Eur J Pediatr. 166:1053–1055. 2007. View Article : Google Scholar : PubMed/NCBI